Cover Image
市場調查報告書

Leber遺傳性視神經病變(LHON)的開發中產品分析

Optic Neuropathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257807
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
Leber遺傳性視神經病變(LHON)的開發中產品分析 Optic Neuropathy - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 59 Pages
簡介

所謂Leber遺傳性視神經病變(以下LHON),是先天性視覺障礙的一種,通常在10∼20多歲發病,不過雖然非常稀少但是也有在幼兒期和中年期之後發病的病例。還有男性比女性發病率高。主要的症狀為,眼睛疼痛和不舒服,發麻,刺痛,視覺朦朧等。易罹病素質中包含著年齡和抽煙、酒精、抗癌劑、化學藥品相關壓力,部分抗生素、氰基等。

本報告提供全球各國的Leber遺傳性視神經病變(LHON)治療用的開發中產品的開發情形相關分析、開發中產品的開發、上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要、最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

LHON概要

治療藥的開發

  • LHON之開發中產品:概要
  • LHON之開發中產品:比較分析

各企業開發中的LHON治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

LHON治療藥:開發中產品一覽(各企業)

LHON治療藥的開發企業

  • Santhera Pharmaceuticals Holding AG
  • Biovista Inc.
  • Genethon
  • Edison Pharmaceuticals, Inc.
  • Alkeus Pharmaceuticals, Inc.
  • GenSight Biologics

LHON:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 艾地苯醌
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • GS-010
  • vatiquinone
  • LHON治療藥
  • BVA-202
  • BVA-203
  • LHON治療藥

LHON治療藥:開發中產品的最新趨勢

LHON治療藥:開發暫停的產品

LHON相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿(共10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8377IDB

Summary

Global Markets Direct's, 'Optic Neuropathy - Pipeline Review, H2 2016', provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy
  • The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects
  • The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Optic Neuropathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Optic Neuropathy Overview
  • Therapeutics Development
    • Pipeline Products for Optic Neuropathy - Overview
    • Pipeline Products for Optic Neuropathy - Comparative Analysis
  • Optic Neuropathy - Therapeutics under Development by Companies
  • Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes
  • Optic Neuropathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Optic Neuropathy - Products under Development by Companies
  • Optic Neuropathy - Products under Investigation by Universities/Institutes
  • Optic Neuropathy - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • BioAxone BioSciences, Inc.
    • Inotek Pharmaceuticals Corporation
    • Ironwood Pharmaceuticals, Inc.
    • PharmatrophiX, Inc.
    • Quark Pharmaceuticals, Inc.
    • Regenera Pharma Ltd.
  • Optic Neuropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BA-240 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IWP-953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-22A4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPI-1007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPh-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trabodenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WSTB-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Optic Neuropathy - Dormant Projects
  • Optic Neuropathy - Product Development Milestones
    • Featured News & Press Releases
      • Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
      • Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
      • Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
      • Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
      • Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
      • Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
      • Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Optic Neuropathy, H2 2016
  • Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Optic Neuropathy - Pipeline by Amgen Inc., H2 2016
  • Optic Neuropathy - Pipeline by BioAxone BioSciences, Inc., H2 2016
  • Optic Neuropathy - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
  • Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Optic Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2016
  • Optic Neuropathy - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
  • Optic Neuropathy - Pipeline by Regenera Pharma Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Optic Neuropathy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Optic Neuropathy, H2 2016
  • Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top